Acasti Pharma Long Term Debt 2014-2024 | GRCE

Acasti Pharma long term debt from 2014 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Acasti Pharma Annual Long Term Debt
(Millions of US $)
2024 $
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $1
2017 $1
2016 $
2015 $
2015 $
2014 $
2014 $
2013 $
2013 $
Acasti Pharma Quarterly Long Term Debt
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31 $1
2018-09-30 $1
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $1
2017-06-30 $1
2017-02-28 $1
2016-11-30
2016-08-31
2016-05-31
2016-03-31
2016-02-29
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2014-02-28
2013-12-31
2013-09-30
2013-06-30
2013-03-31
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00